The purpose of this Phase 1, multicenter, open-label study is to determine the maximum tolerated dose (MTD) of AG-636 and characterize its dose-limiting toxicities (DLTs) when given by mouth to subjects with advanced lymphoma that is refractory to standard treatment. During the dose-escalation part of the study successive cohorts of subjects will be treated with increasing doses of AG-636 in order to determine its maximum tolerated dose (MTD). Subsequently, in the dose-expansion part of the study, additional subjects will be treated at the MTD in order to confirm that dose's safety, tolerability, PK and PD, and to provide an opportunity to detect anti-lymphoma activity. The dose expansion part of the study will support the selection of a dose for future clinical studies (a recommended Phase 2 dose [RP2D]).
A 13-year-old boy with giant accessory spleen underwent spontaneous intrasplenic hemorrhage who presented with recurrent abdominal pain. Contrast-enhanced MRI was mandatory for the diagnosis before surgical procedure.
Deep vein thrombosis after femoral arterial access is a rare complication of left heart catheterization. This case highlights the complex pathophysiology of Deep vein thrombosis following femoral arterial access and the challenges of management strategy selection.
This is a case of a 30-year-old female presenting with fatigue, abdominal striae, unintentional weight gain, and lipodystrophy. A rare diagnosis of ectopic adrenocorticotropic-dependent CS was determined and a neuroendocrine lung tumor was discovered on chest x-ray. After surgical resection, pathology confirmed lung neuroendocrine lung tumor that stained positive for adrenocorticotropic hormone.
This is a case of a a 26-year-old woman who presented with a four-day history of an erythematous swollen left lower limb. She was treated with intravenous clindamycin for suspected cellulitis. However, her symptoms persisted. Punch biopsy revealed findings consistent with erythema nodosum. Two days later, she developed colicky abdominal pain associated with non-bloody diarrhea. Stool culture yielded Salmonella enterica serotype enteritidis. Two days after discharge, she presented again with a right breast abscess for which she underwent incision and drainage along with antibiotic therapy. After discharge, she was symptom-free with complete resolution of the cutaneous lesions.
This is the case of a 9-year-old male who presented with seizures and minor trauma. Imaging showed progression of leptomeningeal enhancement in the setting of increased seizure activity, and biopsy confirmed the diagnosis. The patient received immunotherapy but eventually succumbed to the disease.
According to the BCBS Association, The Blue Cross Blue Shield Association and 18 independent and locally-operated BCBS companies are partnering with Civica Rx to lower the cost of generic prescription drugs and the 18 BCBS companies will provide $55 million to help create a Civica subsidiary. The effort will focus on generics that currently carry a high price tag as a result of limited or no competition.
According to a new report brief released by Center for Medical Economics and Innovation at the Pacific Research Institute, reforming the complex drug supply chain, and ending the current drug pricing system that overcharges patients along with system-wide reforms are what's needed to lower America's healthcare costs. Some states, such as California, have already taken measures to address this, but researchers believe these measures are misguided.
Scientists have discovered that a non-invasive technique that could one day be used to treat Parkinson’s disease, can successfully target a highly specific group of brain cells that play a key role in the development of the condition. In 2015, scientists demonstrated that a form of gene therapy could target and stimulate a group of nerve cells affected by the disease, called cholinergic neurons. These cells degenerate as the disease progresses. Now, thanks to brain imaging technology, they have discovered that their method, which targets cells that produce specific brain chemicals, can also successfully stimulate another type of neuron through cell-to-cell interactions.
In patients with neovascular age-related macular disease, a treat-and-extend ranibizumab regimen is not inferior to injections given at fixed intervals, plus it's more convenient, according to a new clinical trial. The goal in treating macular degeneration, the most common cause of blindness in the western world, is to maximize visual gains and minimize the burden of treatment and visits on patients and their families.